Literature DB >> 28676583

Priority reviews: innovation and safety.

Joel Lexchin1.   

Abstract

Mesh:

Year:  2017        PMID: 28676583      PMCID: PMC5495643          DOI: 10.1503/cmaj.733103

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Experts blame feds for pharma corruption.

Authors:  Lauren Vogel
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262

2.  New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010?

Authors:  Joel Lexchin
Journal:  Arch Intern Med       Date:  2012-11-26

3.  Correction. Health Canada's use of its priority review process for new drugs: a cohort study.

Authors:  J Lexchin
Journal:  BMJ Open       Date:  2015-09-18       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.